Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
-$0.22 today
- Market cap
- $255.25M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
Volume 0.26M
Average 0.74M
QTTB Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Q32 Bio Inc.NASDAQ: QTTB
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 22.5% from a year ago
Cash & equivalents stood at $50.75M at the end of Q1 FY2026, down 22.5% from a year earlier and up 5.1% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Cash & equivalents amounted to 79.7% of total assets at the end of Q1 FY2026, down 3.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -22.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 48.3M USD
- Year-over-year change
- -38.1%
- 4-year CAGR
- -18.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.3M | -38.1% |
| FY2024 | 2024-12-31 | 77.97M | +204.3% |
| FY2023 | 2023-12-31 | 25.62M | -41.6% |
| FY2022 | 2022-12-31 | 43.89M | -59.5% |
| FY2021 | 2021-12-31 | 108.38M | — |
Cash & Equivalents vs competitors
How QTTB compares with its peers on the latest reported figures
- QTTB's Mar 2026 cash & equivalents of $50.75M is the 2nd highest of the 5 companies compared; the peer median is $19.04M.
- Its year-over-year change of -22.5% is the 4th highest of 5, against a peer median of +69.8%.
- Cash & equivalents amounts to 79.7% of total assets for QTTB, versus a peer median of 32.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.49M | +167.6% | -9.9% | 61.1% | |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Mar 2026 | $20.6M | -30.4% | -4.2% | 53.1% | |
| Mar 2026 | $17.48M | +15.7% | +17.7% | 12.4% | |
| Jun 2026 | $8.27M | +123.9% | -11.3% | 3.5% | |
| Peer median (excluding QTTB) | $19.04M | +69.8% | -7.0% | 32.8% | |
Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 108.38M | 43.89M | 25.62M | 77.97M | 48.3M |
| Short-term Investments | 47.49M | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 1.06M | 755K | 555K | 0 |
| Inventory | 0 | 1.75M | 0 | 0 | 0 |
| Other Current Assets | 36.04M | 146K | 83K | 396K | 6.75M |
| Total Current Assets | 191.91M | 46.85M | 28.72M | 81.88M | 55.05M |
| Property, Plant & Equipment (Net) | 17.86M | 9.17M | 8.08M | 7.09M | 6.08M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.95M | 25.81M | 5.65M | 2.6M | 647K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | (20.06M) | 10.26M | 763K | 0 |
| Total Non-current Assets | 19.81M | 14.92M | 18.34M | 10.46M | 6.73M |
| Total Assets | 211.72M | 61.77M | 47.06M | 92.33M | 61.78M |
| Account Payables | 2.37M | 1.44M | 3.47M | 2.99M | 879K |
| Short-term Debt | 246K | 32.4M | 878K | 3.1M | 6.93M |
| Tax Payables | 0 | 570K | 316K | 0 | 0 |
| Deferred Revenue | 3.21M | 14.53M | 0 | 0 | 0 |
| Other Current Liabilities | 11.41M | 2.79M | 3M | 5.68M | 3.54M |
| Total Current Liabilities | 17.23M | 57.87M | 14.11M | 16.47M | 11.35M |
| Long-term Debt | 0 | 5.07M | 43.18M | 9.56M | 3.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.16M | 11.32M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 111.45M | 166.45M | 55M | 0 |
| Total Non-current Liabilities | 24.84M | 134.62M | 215.87M | 70.19M | 8.42M |
| Total Liabilities | 42.07M | 192.49M | 229.98M | 86.66M | 19.76M |
| Common Stock | 6K | 6K | 1K | 2K | 2K |
| Retained Earnings | (424.13M) | (429.14M) | (187.08M) | (234.81M) | (204.99M) |
| Accumulated OCI | (7K) | (404K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 169.65M | (130.71M) | (182.92M) | 5.68M | 42.01M |
| Total Debt | 23.93M | 44.73M | 50.84M | 18.9M | 15.34M |
| Net Debt | (84.45M) | 838K | 25.22M | (59.06M) | (32.95M) |
Q32 Bio Inc.
NASDAQ:QTTB
Intrinsic Alpha fair value
Locked
Current Price
$8.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.